Welcome to our dedicated page for Harte Hanks SEC filings (Ticker: HHS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Harte Hanks, Inc. (NASDAQ:HHS) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered tools to help interpret them. Harte Hanks is a global customer experience and data-driven marketing company operating through Customer Care, Fulfillment & Logistics and Marketing Services segments, and its filings offer detailed insight into these operations, its transformation initiatives and its financial position.
Investors can review current reports on Form 8-K that Harte Hanks files to announce material events, such as quarterly earnings releases, amendments to its asset-based revolving credit facility with Texas Capital Bank, and leadership changes including the appointment of a President to oversee business segments and Project Elevate. These 8-Ks often incorporate press releases that discuss segment performance, EBITDA and Adjusted EBITDA, and balance sheet metrics.
Annual reports on Form 10-K and quarterly reports on Form 10-Q (when available in the feed) provide a more comprehensive view of Harte Hanks’ revenue by segment, cost structure, non-GAAP reconciliations, pension-related items, and risk disclosures. For a company focused on customer experience and data-driven marketing, these filings are central to understanding how Project Elevate, credit facility terms and segment-level trends affect long-term profitability.
Stock Titan enhances these documents with AI-generated summaries that highlight key points from lengthy filings, helping users quickly identify changes in operating performance, liquidity, covenants and transformation progress. You can also use this page to monitor governance and compensation information in proxy materials and to track any future insider transaction reports on Form 4, all in one place and updated in near real time from the SEC’s EDGAR system.
Harte Hanks, Inc. reported fourth-quarter 2025 and full-year 2025 results showing lower revenue but improved bottom-line metrics. Q4 revenue was $39.9 million, down 15.4% from $47.1 million a year earlier, yet net income swung to $2.2 million, or $0.30 per share, from a $2.4 million loss.
For full year 2025, revenue declined to $159.6 million, down 13.9% from $185.2 million in 2024, and operating income fell to $0.4 million from $2.1 million. Even so, net loss narrowed sharply to $0.8 million from $30.3 million, as the prior year included $37.5 million of pension plan termination charges.
EBITDA for 2025 was $4.9 million versus $6.5 million in 2024, while Adjusted EBITDA declined to $6.9 million from $14.0 million, reflecting softer performance across segments. The company ended 2025 with $5.6 million in cash, no debt, and $24.0 million of credit line capacity, emphasizing continued focus on margin expansion and disciplined capital allocation.
Harte Hanks, Inc. reports weaker 2025 revenue but a much smaller net loss. Operating revenue fell to $159.6 million, down 13.9% from $185.2 million in 2024, as demand softened, especially in Revenue Solutions.
Operating income dropped to $0.4 million from $2.1 million, cutting operating margin to 0.2% from 1.1%. Despite this, net loss narrowed sharply to $0.8 million from $30.3 million, mainly due to a steep decline in other expenses. The company continued its "Project Elevate" restructuring, targeting $16.0 million of cost reductions over 2024–2025 and recorded restructuring charges of $1.8 million in 2025 and $2.4 million in 2024.
Harte Hanks Inc. received an updated ownership report on its common stock from Westerly Capital Management, LLC and related parties on a Schedule 13G/A (Amendment No. 8).
The reporting persons state beneficial ownership of 627,000 shares of Harte Hanks common stock, representing 8.5% of the class, with shared voting and dispositive power over all of these shares and no sole voting or dispositive power. This percentage is calculated based on 7,414,794 shares outstanding as of October 31, 2025, as referenced from the company’s Form 10-Q for the quarter ended September 30, 2025. The filers certify the shares were not acquired or held for the purpose of changing or influencing control of Harte Hanks.
Harte Hanks Inc director Genevieve Combes reported an equity grant of company stock. On 12/09/2025 she was awarded 27,861 restricted stock unit (RSU) shares of common stock at $3.23 per share, scheduled to vest 100% on the first anniversary of the grant date.
After this award, she beneficially owns 26,283 common shares directly, plus 27,861 RSU shares from the 2025 grant, 12,048 RSU shares granted on 5/23/2024 that vested on 5/23/2025, and 16,216 RSU shares granted on 8/17/2023 that vested on 8/17/2024, with receipt of the vested RSU shares deferred until a later date.
Harte Hanks Inc. director Bradley Radoff reported receiving 27,861 shares of common stock as restricted stock units (RSUs) on 12/09/2025 at $3.23 per share. These RSUs will vest 100% on the first anniversary of the grant date.
After this grant, he beneficially owns 27,861 RSUs held indirectly, 391,399 shares of Harte Hanks common stock directly, 20,000 shares held indirectly in an IRA, and 12,048 additional shares held directly that vested 100% on 5/23/2025.
Harte Hanks (HHS) filed its Q3 2025 10‑Q, showing softer demand across all segments and a swing to loss. Revenue was $39.5M (down 17% year over year) with operating income of $0.5M versus $1.9M a year ago. After other expenses of $0.2M and income tax expense of $2.6M, the company reported a net loss of $2.3M (basic and diluted EPS $(0.31)).
By segment in Q3: Marketing Services $8.8M and Customer Care $11.6M declined on customer turnover and program timing, while Fulfillment & Logistics $19.1M delivered stronger profitability, lifting segment operating income to $1.7M from $1.1M last year. Year to date, revenue was $119.7M (down 13.3%) and operating income was $0.5M.
Cash and equivalents were $6.5M at September 30, 2025; net cash used in operating activities was $2.5M year to date. The company extended its $25.0M revolving credit facility to June 30, 2028 at SOFR + 2.25%, had $1.0M in letters of credit outstanding, and no borrowings, leaving $24.0M available capacity. Project Elevate restructuring costs were $0.5M in Q3 and $1.5M year to date; total targeted reorganization savings across 2024–2026 are $16.0M. Shares outstanding were 7,414,794 as of October 31, 2025.
Harte Hanks (HHS) furnished a press release announcing financial results for the third quarter ended September 30, 2025. The company provided the update under Item 2.02, and the release is included as Exhibit 99.1.
The information in Item 2.02, including Exhibit 99.1, is furnished and not deemed filed under the Exchange Act. Harte Hanks’ common stock trades on NASDAQ under the symbol HHS.
Harte Hanks reported lower revenue and a small net loss for the quarter ended June 30, 2025.
Revenue fell to $38.6 million for the quarter (down 14.2% year-over-year) and $80.2 million for the six months (down 11.4%). The company recorded a net loss of $0.3 million for the quarter and $0.7 million for six months, equal to basic and diluted losses per share of $0.05 and $0.10, respectively. Cash and cash equivalents declined to $4.8 million at June 30, 2025. Operating expenses declined year-over-year (11.6% for the quarter; 9.6% for six months) as the company reduced labor and other costs and continued its transformation program, Project Elevate, which targets $16.0 million of cumulative savings. The company extended its asset-based revolving Credit Facility to June 30, 2028 and had $24.0 million of borrowing availability after letters of credit.